ClinicalTrials.gg
Not yet recruitingNCT07477327Updated Mar 17, 2026

Is 6 Weeks Immobilization for a Chopart Injury Still State of the Art? Comparison Between Cast Immobilization Versus Functional Treatment

An interventional study of 6 weeks cast immobilization and Rigide sole in Foot Ankle Injuries, sponsored by Hôpital Fribourgeois. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Hôpital Fribourgeois · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Treatment Arms for Randomization

  1. Restrictive treatment: Immobilization in a cast or VACOped boot (lower leg boot with ankle immobilzation) for 6 weeks.

    • Advantage: Provides stable conditions for fracture healing.
    • Disadvantage: Risk of muscle atrophy and ankle joint stiffness due to prolonged immobilization.
  2. Functional treatment: Weightbearing as tolerated using a rigid-sole shoe.

    • Advantage: Allows early mobilization, reduces muscle atrophy, and helps maintain ankle mobility.
    • Disadvantage: Potential concern regarding pain, insufficient fracture stabilization, or pseudarthrosis Study Objectives This research project focuses on the treatment of Chopart fractures. In recent years, the number of diagnosed fractures following ankle sprains has increased. This rise is likely due to improved awareness of these injuries and the more frequent use of advanced imaging techniques such as CT scans (Computed Tomography). However, the optimal treatment strategy for these fractures remains unclear.

Current treatment approaches range from operative management to conservative treatment with 6-8 weeks of immobilization, and more recently to functional treatment protocols. Most of the available evidence consists of case series, representing a low level of evidence. High-quality comparative studies are currently lacking.

As a public hospital, Hospital Cantonal Fribourg (HFR) manages a large number of regional trauma cases, including Chopart injuries, with an incidence of approximately 50 cases per year. At present, treatment at HFR is predominantly conservative, involving 8 weeks of immobilization in a cast or a VACOped boot. While immobilization allows sufficient time for fracture healing, it may result in muscle atrophy and ankle joint stiffness. Recent literature suggests that a more functional treatment approach may lead to promising results. However, it remains unclear whether earlier weightbearing and functional rehabilitation improve overall outcomes or result in prolonged pain and increases the risk of complications. Therefore, the aim of this study is to compare different non-operative treatment strategies using both patient-reported outcome measures and objective gait analysis.

The primary objective of this study is to evaluate patient-reported outcomes following different non-operative treatment strategies for Chopart fractures. In addition, the study will assess differences in gait patterns between the two study arms and correlate these findings with patient-reported outcomes and quality of life. The study also aims to determine the timeline required to regain a normal gait pattern after injury.

Outcome Measures The primary outcome will be patient-reported functional outcome and quality of life, assessed using a 22-item questionnaire combining the EFAS Score (European Foot and Ankle Society) and the Short Form-12 health survey. The secondary outcome will be objective gait analysis parameters.

02

Conditions studied

  • Foot Ankle Injuries

Browse trials for

03

In context

Ankle Injuries

354 studies on the registry are indexed under Ankle Injuries; 77 are open to participants now.

This study's planned enrollment of 70 is above the median of 54 across 274 interventional studies indexed under Ankle Injuries.

Browse Ankle Injuries studies →

Lead sponsor

Hôpital Fribourgeois is the lead sponsor of 18 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged above 18 years
  • Patient with a pure ligament Chopart injury or bony avulsion of the ligaments of the Chopart joint line
  • Patient expected to complete length of study

Exclusion criteria

Exclusion Criteria:

  • Patient which does not understand the (due to language capacity or mental capacity)

    • Patient non ambulating before time of injury
    • Patient treated for the fracture outside of Hopital Cantonal Fribourg (the study side)
    • Patient treated for a fracture at the same foot/ ankle before
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Restrictive treatment:

    Immobilization in a cast or VACOped boot for 6 weeks

    Other: 6 weeks cast immobilization

  • Other
    Functional treatment

    Weightbearing as tolerated using a rigid-sole shoe.

    Other: Rigide sole

Interventions

  • Other6 weeks cast immobilization

    6 weeks cast immobilization

  • OtherRigide sole

    6 weeks of weight bearing as tolerated

06

What researchers measure

Primary outcomes

  1. Patient reported outcome

    European foot and ankle society score; minimum score of 0 points (worst possible) and a maximum score of 24 points (best possible).

    Time frame: 6 weeks, 3 months, 6 months, 1 year

Secondary outcomes

  1. Quality of life

    SF-12: The Short Form-12 health survey produces two main summary scores-the Physical Component Summary (PCS) and Mental Component Summary (MCS)-which are normed to a mean of 50 and a standard deviation of 10 in the general U.S. population. Scores typically range from 0 to 100, where higher values indicate better

    Time frame: 6 weeks, 3 months, 6 months, 1 year

Other outcomes

  1. Gait analysis

    Will be performed by the Nushu: NUSHU smart shoes by Magnes AG provide medical-grade, real-time, in-shoe gait analysis and sensory feedback. Using AI-powered sensors, the system tracks over 35 gait parameters (e.g., speed, stride length, cadence, symmetry) to monitor disease progression. We already used the analysis for malleolar fractures

    Time frame: 6 weeks, 3 months, 6 months, 1 year

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 141 non-industry interventional studies with no phase under Ankle Injuries, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 31. This study's planned 12 months is above that.

Counting every sponsor, half of 144 studies reached it within 9 months; a quarter within 4 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 17, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2030
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07477327
Lead sponsor
Hôpital Fribourgeois
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2030 (estimated)
Last update
Mar 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion